Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy

Diabetes

Volumn 52, Issue 3, 2003, Pages 667-674

  Phillips, Susan A ^a,b   Ciaraldi, Theodore P ^a,c   Kong, Alice P S ^a,c   Bandukwala, Rahil ^a,c   Aroda, Vanita ^a,c   Carter, Leslie ^a,c   Baxi, Sunita ^a   Mudaliar, Sunder R ^a,c   Henry, Robert R ^a,c  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

FFA, free fatty acid; GDR, glucose disposal rate; HGO, hepatic glucose output; HWS, HEPES washing salts; IL, interleukin; LND, lean nondiabetic; LT2D, lean type 2 diabetic; MW, molecular weight; OND, obese nondiabetic; OT2, obese type 2 diabetic

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIDIABETIC AGENT; GLIBENCLAMIDE; METFORMIN; SULFONYLUREA; TROGLITAZONE;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; AGE; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN SECRETION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; WEIGHT;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ADULT; AGED; BIOPSY; CHROMANS; CULTURE MEDIA, CONDITIONED; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METFORMIN; MIDDLE AGED; MOLECULAR WEIGHT; OBESITY; PROTEINS; THIAZOLES; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 0037342120     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.3.667     Document Type: Article

References (49)

1. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adipose Most Abundant Gene Transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
2. Scherer PE, Williams S, Fogliano MF, Baldini G, Lodish HF. A novel serum protein similar to C1q produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
3. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996
4. Nakano Y, Tobe T, Choi-Miura NH, Mazada T, Tomita M: Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 120:803-812, 1996
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotto K, Shimomura I, Nakamura T, Miyaoka K: Paradoxical decrease of an adipocyte-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
6. Hotta K, Funahashi T, Arita Y, Takahash M, Matsuda M, Okamoto Y, Iwasashi H, Kuriyama H, Ouchi N, Maeda K: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
7. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126-1133, 2001
8. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE: Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
9. Yang W-S, Lee W-J, Funahashi T, Tanaka S, Matsuzawa Y, Chao C-L, Chen C-L, Tai T-Y, Chuang L-M: Weight reduction increases plasma levels of an adipose-derived anti-inflamatory protein, adiponectin. J Clin Endocrinol Metab 3815-3819, 2000
10. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPAR-γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
11. Combs TP, Wagner JA, Berger J, Doebber T, Wang W.-J., Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB: Induction of adipocyte complement-related protein of 20 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007, 2002
12. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM: The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 51:2968-2974, 2002
13. Mudaliar S, Henry RR: New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 52:239-257, 2001
14. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1966
15. Inzucchi SE, Maggs DG, Spollet GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
16. Cusi K, DeFronzo RA: Metformin: a review of its metabolic effects. Diabetes Rev 6:89-131, 1998
17. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Diebber T, Fuji N, et al: Role of AMP-activated protein kinase in the mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
18. Thornburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR: Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin dependent (Type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522-529, 1990
19. Desbuquois B, Aurbach GD: Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radio-immunoassays. J Clin Endocrinol Metab 33:732-738, 1971
20. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, et al: Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25:1-8, 2002
21. Kim Y-B, Ciaraldi TP, Kong A, Kim D, Chu N, Mohiden P, Mudaliar S, Henry RR, Kahn BB Troglitazone, but not metformin, restores insulin-stimulated phosphoinositidyl 3-kinase activity in skeletal muscle of type 2 diabetic subjects. Diabetes 51:443-448, 2002
22. Ciaraldi TP, Kong APS, Chu NV, Kim DD, Baxi S, Loviscach M, Plodkowsld R, Reitz R, Caulfield M, Mudaliar S, et al: Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51:30-36, 2002
23. Ciaraldi TP, Kolterman OG, Olefsky JM: Mechanism of the post-receptor defect in insulin action in human obesity: decrease in the intrinsic activity of the glucose transport system. J Clin Invest 68:875-880, 1981
24. Rodbell M: Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239:375-380, 1964
25. Hirsch J, Gallian E: Methods for the determination of adipose cell size in man and animals. J Lip Res 9:110-119, 1968
26. Thies RS, Molina JM, Ciaraldi TP, Freidenberg GR, Olefsky JM: Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese, and NIDDM subjects. Diabetes 39:250-259, 1990
27. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 27:680-685, 1970
28. Tsao T-S, Murrey HE, Hug C, Lee DH, Lodish HF: Oligomerization state-dependent activation of NF-kB signaling pathway by adipocyte compliment-related protein of 30 kDa (Acrp30). J Biol Chem 277:29359-29362, 2002
29. Berg AH, Combs TP, Scherer PE ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol & Metab 13:84-89, 2002
30. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11:327-332, 2000
31. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, Rafaeloff-Phail R, Seng T, Suter TM, Sluka JP, et al: Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 1:81-88, 2000
32. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, et al: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141, 2002
33. Hirose H, Kawai T, Yamamoto Y, Tamyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, et al: Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in japanese male patients with type 2 diabetes. Metabolism 51:314-317, 2002
34. Fruebis J, Tsao T-S, Javorschi S, Ebbets-Reed D, Erickson MRS, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005-2010, 2001
35. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001
36. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7:947-953, 2001
37. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigamia M, Kuriyama H, Kishida K, Nishizawa H, et al: Adipocyte-dericed plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001
38. Kelly IE, Han TS, Walsh K, Lean ME: Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293, 1999
39. Kawai T, Takei I, Oguma Y, Ohashi N, Oguchi S, Katsukawa F, Hirose H, Shiumada A, Watanabe K, Saruta T: Effects of troglitazone on fat distribution in the treatment of male type 2 diabetics. Metabolism 49:1102-1107, 1999
40. Auwerx J: PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999
41. Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault M-F, Dugail I, Morin J, Auwerx J, Perre P: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399, 1997
42. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee KK, et al: Activators of peroxisome proliferator-activated receptor gamma have depot specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997
43. Schaffler A, Orso E, Palitzsch KD, Buchler C, Drobnik W, Furst A, Scholmerich J, Schmitz G: The human apM-1, and adipocyte-specific gene linked to the family of TNF's and to genes expressed in activated T cells, is mapped to chromosome Iq21.3-q23, a susceptibility locus identified for familial combined hyperlipidaemia (FCH). Biochem Biophys Res Commun 260:416-425, 1999
44. Saito K, Tobe T, Minoshima S, Asakawa S, Sumiya J, Yoda M, Nakano Y, Shimizu N, Tomita M: Organization of the gene for gelatin-binding protein (GBP28). Gene 229:67-73, 1999
45. Barth N, Langmann T, Scholmerich J, Schmitz G, Schaffler A: Identification of regulatory elements in the human adipose most abundant gene transcript (apM-1): role of SP1/SP3 and TNF-a as regulatory pathways. Diabetologia 45:1425-1433, 2002
46. Wang Y, Xu A, Knight C, Xu LX, Cooper GJS: Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. J Biol Chem 277:19521-19529, 2002
47. Sato C, Yasukawa Z, Honda N, Matsuda T, Kitajima K: Identiifcation and adipocyte differentiation-dependent expression of the unique disialic acid residue in an adipose tissue-specific glycoprotein, Adipo Q. J Biol Chem 276:28849-28856, 2001
48. Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46:1579-1585, 1997
49. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, Vehkavaara S, Goto T, Halavaara J, Hakkinen AM, Yki-Jarvinen H: Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50:2337-2343, 2001